

1 *Article*

2 **Assessment of Attitude and Hesitancy Towards Covid-19 Vaccine among**  
3 **Hepatitis B and C Patients in Pakistan**

4

5 **Short Title:** Refusal to covid-19 vaccine among viral Hepatitis patients in Pakistan

6

7 Farheen Shafiq<sup>1</sup>,

8 <https://orcid.org/0000-0003-3658-9729>

9 Mahreen ul Hassan<sup>2\*</sup>

10 <https://orcid.org/0000-0002-5524-9765>

11 Sadia Butt<sup>3</sup>

12 <https://orcid.org/0000-0002-3631-3354>

13 Sadia sidique<sup>4</sup>

14 <https://orcid.org/0000-0001-6483-3579>

15 Nazia Akbar<sup>5</sup>

16 <https://orcid.org/0000-0003-2203-4933>

17 Azra<sup>6</sup>

18 <https://orcid.org/0000-0002-3088-2345>

19 Irshad Rehman<sup>7</sup>

20 <https://orcid.org/0000-0002-2724-6946>

21

22 **\*Correspondence:**

23 **Dr. Mahreen ul Hassan**

24 <https://orcid.org/0000-0002-5524-9765>

25 Email: microkust@sbbwu.edu.pk

26 Contact no. 03348483041

27 78 Western Bank

28 Firth Court

29 Department of Bioscience

30 University of Sheffield, UK

31 S10 2TN

32 Sheffield, South Yorkshire

33 United Kingdom

## 34 **ABSTRACT**

35 **OBJECTIVE:** The research aimed to evaluate the attitude and perceptions towards the covid-19  
36 vaccine among Hepatitis B and C patients in Peshawar, Khyber Pakhtunkhwa, Muzaffarabad,  
37 Azad Kashmir, Pakistan.

38 **METHODS:** A survey-based study was adopted to evaluate the attitude of Hepatitis B and C  
39 patients towards immunization against covid-19 in Peshawar (KPK) and Muzaffarabad (AJK)  
40 cities of Pakistan. The study continued from January 2020 to February 2021. Participants were  
41 also assessed for their perception towards covid-19 vaccination.

42 **RESULTS:** A total of 839 (33.6%) individuals participated in the study. About 52 % of  
43 Hepatitis B patients were immunized against Covid-19, whereas the number of Hepatitis C  
44 patients was recorded at around 48%. About 53.7 % of participants refused to get the vaccine  
45 without any reason. About 63.2% of patients showed concern about the insufficient data  
46 available on the vaccine safety and efficacy published by the Public Health Department.  
47 Individuals with higher education were observed to be more open towards vaccination than those  
48 without a formal education. More than half of the participants (61.5 %) were concerned about the  
49 interference of the vaccine with their hepatitis treatment whereas 54.7 % patients refused vaccine  
50 because of a poor liver condition.

51 **CONCLUSIONS:** The data indicated that limited data availability regarding the vaccine  
52 efficacy in viral hepatitis patients and negative attitudes of people toward covid-19 vaccination is  
53 the main cause of Covid-19 vaccination refusal among hepatitis B and C patients.

54 **DESCRIPTORS:** Hepatitis B, Hepatitis C, covid-19, immunization, vaccine refusal, Pakistan.

## 55 **INTRODUCTION**

56 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the 7th human coronavirus,  
57 was reported in Wuhan, Hubei province, China, in January 2020<sup>1-2</sup>. In early 2020, the World  
58 Health Organization (WHO) declared it a pandemic and requested the world to take strict  
59 measures to control the disease as there was no effective treatment available, and the death toll  
60 was rising every hour across the world<sup>3</sup>.

61 The SARS-CoV-2 is an airborne virus which can be transmitted through air therefore effective  
62 preventive measures like social distancing, frequent handwash and wearing a mask in the  
63 absence of a valid treatment or vaccine to control the disease was imperative<sup>4</sup>.

64 Patients with covid-19 may have abnormal liver function or hepatic dysregulation, which may  
65 identify as cholestasis, hepatitis, or both. In an early study from China, increased total bilirubin  
66 was observed in 18 (18%) patients and higher serum alanine aminotransferase (ALT) was  
67 recorded in 28 (28%) of 99 individuals with covid-19<sup>5</sup>.

68 It is suggested that SARS-CoV-2 may exacerbate liver damage in individuals with chronic viral  
69 hepatitis<sup>6</sup>. According to Xu et al.<sup>7</sup> (2020), liver dysfunction occurs more often and more severely  
70 as covid-19 progresses. Liver function tests are typically normal or somewhat raised in the early  
71 stages of SARS-CoV-2 infection. Histological examination of the liver reveals syncytial  
72 multinuclear hepatocytes, microvascular steatosis, and little lobular and portal activity.

73 The cytokine storm caused by the progression of severe covid-19 cases requiring strong  
74 immunosuppressive therapy has raised the problem of recurrence of HBV infections in the  
75 patients with a history of HBV<sup>8</sup>.

76 In a study conducted by Ronderos et al.<sup>9</sup> (2021), patients with covid-19 having history of  
77 hepatitis C virus (HCV) or seropositivity for HCV infection have an increased susceptibility to  
78 SARS-CoV-2 infection, which is a strong predictor of in-hospital mortality regardless of  
79 preexisting conditions, laboratory results upon admission, or the severity of covid-19-induced  
80 liver injury.

81 With an estimated 9.8 million chronic HCV patients, Pakistan has the second-highest burden of  
82 HCV infection in the world<sup>10</sup>. Unscreened blood transfusions, a history of hospitalization, dental  
83 work, tattooing, body piercing, the use of injections, and a history of surgery are the main risk  
84 factors for the transmission of HCV<sup>11</sup>. According to government statistics, around 2.5% of  
85 Pakistan's population was infected with HBV in 2008. There was a 5% rise in HCV-related  
86 mortality and an 8% increase in HBV-related deaths between 2015 and 2019<sup>10</sup>.

87 According to World Health Organization vaccination is an easy, safe, and efficient way to avoid  
88 infection especially in the absence of an effective therapy as in the case of covid-19<sup>12</sup>.

89 Vaccination is the most significant medical intervention in the human history which has largely  
90 eradicated the infectious diseases that formerly claimed the lives of millions of people<sup>13</sup>.  
91 Currently, more than 30 infectious diseases could be avoided with the use of vaccinations<sup>14</sup>.  
92 According to an estimation, the immunization against covid-19 have prevented thousands of  
93 deaths and saved millions of people from getting infection in England and United States till June  
94 2021<sup>15-16</sup>.

95 Pakistan is also badly affected by covid-19 pandemic. Currently there are 1,573,922 confirmed  
96 covid-19 cases from which 2,928 are marked as active in different areas of Pakistan and about  
97 30,625 causalities have been observed from 2020 to date<sup>17</sup>.

98 The Chinese government sent more than 500,000 doses of the Chinese Sinopharm vaccine to  
99 Pakistan in February 2021, and the Pakistani government opted to prioritize immunizing  
100 frontline healthcare workers<sup>18</sup>. Pakistan initially restricted immunization to those aged 18 and  
101 older before expanding the program. The government was placing a higher priority on heavily  
102 populated metropolitan centers and "hotspot" locations, where the coronavirus transmits more  
103 rapidly than in more distant rural communities<sup>19</sup>. It is estimated that about 69.9 % population in  
104 Pakistan has taken at least on dose of covid-19 vaccine. The number is not very discouraging but  
105 nature of disease and its transmission along with the emergence of new Corona virus variants  
106 every 6 month makes it crucial to get the entire population immunized in limited time to control  
107 the disease<sup>17</sup>.

108 Vaccine hesitancy is one of the top 10 global health problems, according to the World Health  
109 Organization<sup>20</sup>. Fear of the covid-19 vaccination is a growing problem that Pakistan is also  
110 dealing with. It is one of the nations with lowest vaccination rates<sup>21</sup>. Myths such as the vaccine  
111 causes sterility, the pandemic is a foreign conspiracy, or the virus is harmless are common  
112 contributors to the hesitation towards covid-19 vaccination<sup>22</sup>.

113 In current study have sought to understand the current level of awareness of covid-19  
114 transmission, symptoms, and preventive measures specifically among Hepatitis B and C patients.  
115 The study also aimed to identify the risk variables that contribute to ambivalence towards covid-  
116 19 vaccination among hepatitis patients residing in KPK and AJK, Pakistan.

## 117 **METHODOLOGY**

## 118 **Study Location and Settings**

119 Survey-based research was conducted in Peshawar and Muzaffarabad from January 2020 to  
120 February 2021. A questionnaire was prepared for the study. An epidemiologist, field surveyor,  
121 and health care practitioner assisted in the development of a questionnaire. To calculate the  
122 reliability score and Cronbach alpha, the questionnaire was pretested in a pilot study.

## 123 **Sample Size and Exclusion Criteria**

124 For the evaluation of the knowledge and perception of the hepatitis B and C patients toward  
125 covid-19 and the vaccination program the questionnaire was distributed throughout the  
126 community where these patients were easily accessible. Hepatitis B and C patients age 18 years  
127 and above were deemed eligible. Participants who refused to provide any information or who  
128 were temporary residents were barred from participating. The questionnaire was created to  
129 identify potential challenges to covid-19 immunization.

## 130 **Designing and Validating the Questionnaire**

131 Following a thorough review of the relevant literature, a questionnaire was designed. It was  
132 composed in English, then translated into Urdu and Pushto for participants before translated back  
133 to English for analysis. The questionnaire was divided into two sections, each with 16 questions.  
134 Section one had ten questions that assessed demographic data such as age, gender, race, income,  
135 marital status, and so on. The next section included 16 questions designed to test participants'  
136 knowledge and perceptions about covid-19 and its vaccination.

## 137 **Statistical Analysis**

138 Data evaluation was performed through SPSSv21 statistical package.

## 139 **Ethical Approval and Consent of Participants**

140 This study was approved by the Research and Ethics Committee of Shaheed Benazir Bhutto  
141 Women University Peshawar, Pakistan. A filled and signed informed consent form was collected  
142 from each participant before the participation. All the information of the participants is kept  
143 confidential.

## 144 **RESULTS**

### 145 **Demographic Details of the Respondents**

146 A total of 839 responses were collected, of which 36.1% (303) were female and 63.9% (536)  
147 were from male respondents. Table 1 displays the demographic data (age, gender, place of  
148 residence, educational background, occupation, and monthly income) of the survey respondents.  
149 About 48% responses were collected from Hepatitis B patients whereas the response rate of  
150 Hepatitis C patients was 52 %. Age-wise most of the patients were young (57.1%) while it was  
151 observed that the number of respondents were mostly male (63.9 %) that could be due to the  
152 cultural barriers in the area. The data generated through this study revealed the about 35.5%  
153 hepatitis patients were still unvaccinated due to various reasons.

154 **Table 1. shows demographic data frequencies of the participants. (n = 839).**

### 155 **Approved Vaccines in Pakistan**

156 In Pakistan, every person above age 18 was bound to get one of the approved Covid-19 vaccines  
157 to minimize the devastating effects of pandemic according to National Action Plan for Corona  
158 virus disease (covid-19) Pakistan<sup>a</sup> (Table S1). For the purpose, Government of Pakistan worked  
159 tirelessly making the best vaccines widely available to the public. As a result, about 10% of the  
160 population received the first by the mid of year 2021. The information presented in Table 6 was  
161 generated as a secondary data by utilizing all the reliable resources available e.g., National  
162 Institute of Health Pakistan<sup>b</sup>, WHO<sup>c</sup> and dedicated website for covid-19 related information by  
163 the Ministry of National Health Services Pakistan<sup>d</sup>. Likewise, it was advised that everyone with a  
164 known underlying disease, including those with hepatitis, immunize themselves against covid-  
165 19.

166 **Table 2- Commercially available Vaccines approved by the Government of Pakistan.**

167 It was observed during the study that around 65 % participants were fully immunized (Figure  
168 1a), and rest of the participants refused after taking first dose to immunize due to some reasons  
169 (Figure 1b).

---

<sup>a</sup> <https://www.nih.org.pk/wp-content/uploads/2020/04/COVID-19-NAP-V2-13-March-2020-1.pdf>

<sup>b</sup> <https://www.nih.org.pk/public/novel-coronavirus-2019-ncov>

<sup>c</sup> <https://covid19.who.int/region/emro/country/pk>

<sup>d</sup> <https://covid.gov.pk/>

170 **Figure 1a. No. of patients receiving covid-19 vaccines from approved pharmaceuticals. b. No. of**  
171 **Patients refused to get immunized.**

172 The main objective of this study was to evaluate the hepatitis patients' awareness of the covid-19  
173 vaccination and the fears that were keeping them from receiving the vaccine. For the purpose a  
174 detailed interview was arranged with each participant and their answer were recorded for further  
175 analysis.

176 **Attitude and Perceptions towards covid-19 vaccination**

177 The questionnaire was split in two parts i.e., part A (Table 3a) where patients were assessed why  
178 they chose to get immunized against covid-19. Part B (Table 3b) was specifically designed for  
179 the patients who refused to take covid vaccine.

180 The questionnaire A analysis revealed that most participants (79.5%) were happy to get  
181 vaccinated because there were no charges of that vaccine as compared to the Hepatitis C vaccine  
182 available in the markets (Table 3a). Many participants (76.9%) believed that the vaccine would  
183 protect them from covid-19. About 76.5% people claimed that they were encouraged when they  
184 realized that other hepatitis patients were also getting vaccine. As a reflection of their confidence  
185 in their doctors, 469 out of 710 people (71.2% of the total) vaccinated themselves after medical  
186 professionals encouraged them to do so. Yet 374 (56.8%) patients showed concern about the  
187 insufficient data available on the vaccine safety and efficacy published by the Public Health  
188 Department.

189 **Table 3a. Assessment of patients choosing covid-19 vaccine for protection. b. Question statements to**  
190 **assess Hepatitis patient for refusing covid-19 vaccine.**

191 There were many explanations given by individuals when asked why they didn't want to be  
192 vaccinated (Table 3b). About 74.1 % of participants had a view that precautionary measures like  
193 social distancing and wearing a mask or visor could protect them from getting covid-19  
194 infection. Some people refused (63.2 %) to get vaccination simply because they did not have  
195 enough information about the vaccine due to unavailability of literature regarding outcomes of  
196 covid vaccination. Interestingly, half of the patients (53.7 %) were simply against any type of  
197 immunization whatever vaccine it was and perceived the immunization as a part of foreign  
198 agenda. However, 181 (61.5 %) patients were worried that the vaccine might interact with their  
199 hepatitis therapy as there is no published data available which can prove it wrong; people don't



200 believe in assumptions especially in case of a health-related issue. The study also revealed that  
201 about 54.7 % of total participants were concerned about their liver condition as they were already  
202 dealing with a liver infection. The fear of an over-burdened liver cannot be overlooked. More  
203 than half (57.5 %|) of the patients who were against the vaccination were of view that there is no  
204 point to get vaccination if it is not protecting you against the infection. Around 58.5 %  
205 participants were of view that they have immunity against the disease due to the previous covid  
206 infection. Unfortunately, some patients (12.2 %) got allergic reactions after getting first dose due  
207 to which they feared to try another type of covid vaccine.

### 208 **Correlation between various parameters**

209 Table 4a showed positive and negative correlation between various parameters of hepatitis  
210 patients with respect to the trend towards covid-19 vaccine. A very strong relationship (.104\*\*)   
211 was found among the self-employed people toward the covid vaccine as compared to the people  
212 related to other sources of income. The trend showed that there was a significant difference  
213 among the people of various education levels. The participants having higher levels of education  
214 were more agreed to get vaccinated against covid-19 as compared to others. Surprisingly,  
215 participants having high incomes were showed a highly significant difference and were less  
216 likely to get vaccinated (-.119\*\*) and same was the trend seen in case of females (-0.018). All  
217 age groups showed a weak relationship between patients and their attitude towards the covid  
218 vaccine. A negative correlation was seen in case of ethnicity and location. It was revealed that  
219 participants from Punjabi origin were reluctant (-0.064) to get vaccinated as compared to  
220 Kashmiri and Pathans. The study also revealed that less people from Muzaffarabad AJK were get  
221 vaccinated (-0.022) than those from Peshawar, KPK.

222 **Table 4a. Correlation between different variables of Hepatitis B and C patients with the**  
223 **covid-19 vaccine approval or rejection. b. Spearman correlation between different variables**  
224 **and covid-19 vaccine.**

### 225 **Relationship between Demographic Characteristics and Responses of Participants**

226 Associations of different characteristics were made against the participants' knowledge of covid-  
227 19 (Table 4b). First, education levels of the participants were evaluated against the use of mask  
228 by the participants. It was observed that the use of mask was significantly less among individuals  
229 with lower education levels as compared to individuals with higher education (P 0.064).



230 However, non-significant relationships were present between education level and other aspects  
231 of our study such as attending social gatherings, frequent hand washing, and covid-19 as a  
232 bioweapon. Second, income levels of the participants were analyzed against various factors. A  
233 significant relationship was found among the income level of the participant and their affinity to  
234 join social gatherings during the covid-19 pandemic. It was observed that respondents with lower  
235 income levels were more likely to attend gatherings as compared to higher income respondents.  
236 Similarly, income level was also found to be associated with the subjects' use of mask.  
237 Participants with higher income levels were wearing N95 and surgical masks, whereas cloth  
238 masks were usually used by lower-income respondents. Terminally higher- and lower- income  
239 category subjects wore fewer masks as compared to middle-income-range groups. More  
240 participants in the lower-income category had to leave their jobs or had their business shut down  
241 during the covid-19 pandemic as compared to higher-income respondents. Likewise, more  
242 women have left their jobs as compared to their male counterparts. However, business shutdown  
243 trend mainly affected the male gender. Moreover, the males were found to wear mask more often  
244 than the females. Females usually wore N95 masks, whereas male respondents relied more on  
245 surgical masks or cloth masks. On the contrary, no significant associations were present among  
246 all the characteristics with hand-washing practices and the use of covid-19 as bioweapons.

## 247 **DISCUSSION**

248 In Pakistan, the combined number of persons infected with hepatitis B virus (HBV) and hepatitis  
249 C virus (HCV) is over 15 million<sup>12</sup>. Free treatment for viral hepatitis is being offered throughout  
250 the nation thanks to the Hepatitis Prevention and Treatment Program and other government-  
251 funded initiatives<sup>23</sup>. At a time when a worldwide effort to eliminate viral hepatitis was essential,  
252 covid-19 placed a significant burden on national healthcare systems. According to Mustafa et  
253 al.<sup>24</sup> (2021), with the rise of covid-19 cases in early 2020, a sharp decline in visits of viral  
254 hepatitis patients was observed to their respective clinics across Pakistan. However, an estimated  
255 325 deaths because of viral hepatitis were also reported each day. The data suggested that there  
256 was a clear shift of priority towards the Covid patients due to unavailability of a valid treatment  
257 and increased number of casualties.

258 Current study is unique as it primarily examined how the Hepatitis B and C patients residing in  
259 Peshawar KP and Muzaffarabad AJK have responded to the covid-19 immunization program.

260 Currently no data is available regarding concerns of hepatitis patients in the area, therefore, we  
261 have assessed the participants concerns regarding the vaccine and compared it with the other  
262 studies conducted in the world.

263 As described in the Health Belief Mode, the preventive actions, like getting a vaccination,  
264 depend on how people see the risks of disease and how they perceive the effectiveness, benefits,  
265 and costs of these actions<sup>25</sup>. Pakistan and Afghanistan are two countries where nation-wide  
266 immunization has always been challenging as we have seen in the case of polio eradication  
267 program according to Shafique et al.<sup>26</sup> (2021). In this study it was initially decided to contact  
268 maximum number of viral hepatitis patients residing in the study area. However, it was observed  
269 that most of the patients avoid such interviews due to some reasons. Therefore, we could succeed  
270 to interview around 839 patients. The survey revealed that majority of the participants (79.5%)  
271 were open to vaccination which shows appositve attitude towards the covid-vaccination. The  
272 reason might be the easy availability of the vaccine and an active covid-19 eradication program  
273 in which healthcare workers are going door to door to make sure everyone has got vaccinated.  
274 The results were even better than a similar study conducted by Tahir et al.<sup>27</sup> in 2021.

275 However, there are still number of individuals which are not immunized due to some reason  
276 which is a real concern. It is also notable that majority of the individuals who participated in this  
277 study was between the age of 18 and (57.1 %) which indicates that young generation is more  
278 open to express their opinion about health issues. There were mixed responses when the  
279 participants were asked whether a patient suffering from viral hepatitis should get immunized.

280 Most of the patients (54.7 %) refused to get fully vaccinated despite the government's strict  
281 orders because they were worried about their liver condition. Unfortunately, there is not much  
282 data about the effect of covid vaccines on the liver of hepatitis B and C patients specifically.  
283 Therefore, it is nearly impossible to persuade a person for getting a vaccination with a poor liver  
284 condition. Furthermore, there are some studies that have reported the postvaccination  
285 Autoimmune Hepatitis (AIH)<sup>28-32</sup> which makes it essential to study the health of viral hepatitis  
286 patients after vaccination to devise a better strategy for hepatitis patients in order to prevent  
287 covid-19.

288 More than half of the patients (57.5 %) who refused to take the 2<sup>nd</sup> dose individuals believed that  
289 covid-19 vaccination might not protect them from the covid-19 infection because they got ill or  
290 observed that people contracted infection even getting vaccinated. The concern is authentic;  
291 there are many cases reported around the world where vaccines have failed to prevent individuals  
292 from the disease. For instance, in a recent study Jain et al.<sup>33</sup> (2021) reported that despite its  
293 effectiveness in preventing masses from the adverse effects of covid infection the covid vaccine  
294 was not proved suitable for certain individuals and postvaccination infection even deaths have  
295 been raised many questions on the efficacy of the vaccine especially in patients with  
296 vulnerability.

297 There were a few participants (12.2 %) who were covid against the vaccination because they  
298 developed adverse reactions after getting the 1<sup>st</sup> dose of covid vaccine. This concern was not  
299 baseless as many though rare but incidents regarding hypersensitivity reaction to covid vaccine  
300 have been reported since 2020 vaccine roll out<sup>34</sup>.

301 About 218 (74.1 %) out of total participants believed that strict Standard Operating Procedures  
302 (SOPs) could prevent them from infection. Their belief was not wrong as we have seen that strict  
303 precautionary measures have saved masses when there was no vaccine available during the  
304 pandemic back in 2020. In random studies Kissler et al.<sup>35</sup> (2020) and Moosa<sup>36</sup> (2020) analyzed  
305 that social distancing has appeared to be quite effective to contain the covid infection when there  
306 was no vaccine available. Similarly, Hsieh et al<sup>37</sup>. 2020, reported that preventive measures such  
307 as social distancing, using Personal Protective Equipment (PPE), and frequent handwashing, etc.  
308 at a personal level could be significantly helpful to control the covid infection in the absence of  
309 other interventions. However, their approach to avoid covid-19 infection was not realistic. It is  
310 impossible to avoid social contact in this fast-paced life and sometimes SOPs are not enough. It  
311 is observed in various studies though minimal but there are still chances to get infected by  
312 following SOPs only<sup>38</sup>.

## 313 **CONCLUSION**

314 It was concluded that despite a successful covid-19 prevention program in Pakistan the concern  
315 towards the safety and efficacy of covid vaccine is still there. The study revealed that the reason  
316 to refuse vaccination cannot be neglected as they are genuine and need to be addressed carefully.

317 Additionally, addressing the issues regarding vaccine refusal requires genuine data  
318 demonstrating the benefits of vaccines in viral hepatitis patients is inevitable in order to resolve  
319 the ambiguity related to covid vaccination efficacy.

## 320 **LIMITATIONS IN STUDY**

321 Despite many efforts for making this study possible, it has a few limitations. First, the study area  
322 was confined to only two cities Peshawar and Muzaffarabad which is not enough to portray a  
323 clear picture of the current situation in Pakistan. Secondly, the resistance towards covid-19  
324 vaccination-related reporting also makes data collection difficult. Natives especially hepatitis  
325 patients usually do not want to take part in such studies to avoid stigmatization.

326

## 327 **REFERENCES**

- 328 1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL,  
329 Chen HD. A pneumonia outbreak associated with a new coronavirus of probable bat  
330 origin. *nature*. 2020 Mar;579(7798):270-3.
- 331 2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY,  
332 Yuan ML. A new coronavirus associated with human respiratory disease in China.  
333 *Nature*. 2020 Mar;579(7798):265-9.
- 334 3. World Health Organization Coronavirus Disease 2019(COVID-19) Situation Report-97.  
335 Available from: [https://www.who.int/docs/default-source/coronaviruse/situation-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200426-sitrep-97-covid-19.pdf)  
336 [reports/20200426-sitrep-97-covid-19.pdf](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200426-sitrep-97-covid-19.pdf).
- 337 4. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Bio Medica: Atenei*  
338 *Parmensis*. 2020;91(1):157.
- 339 5. Liao M, Liu H, Wang X, Hu X, Huang Y, Liu X, Brenan K, Mecha J, Nirmalan M, Lu  
340 JR. A technical review of face mask wearing in preventing respiratory COVID-19  
341 transmission. *Current Opinion in Colloid & Interface Science*. 2021 Apr 1;52:101417.
- 342 6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T.  
343 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus

- 344 pneumonia in Wuhan, China: a descriptive study. *The lancet*. 2020 Feb  
345 15;395(10223):507-13.
- 346 7. Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genescà J,  
347 Gill US, James TW, Jones PD, Marshall A. High mortality rates for SARS-CoV-2  
348 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary  
349 results from an international registry. *Journal of hepatology*. 2020 Sep 1;73(3):705-8.
- 350 8. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y.  
351 Pathological findings of COVID-19 associated with acute respiratory distress syndrome.  
352 *The Lancet respiratory medicine*. 2020 Apr 1;8(4):420-2.
- 353 9. Baroiu L, Anghel L, Tatu AL, Iancu AV, Dumitru C, Le□e AC, Drăgănescu M, Năstase  
354 F, Nicule□ E, Fotea S, Nechita A. Risk of hepatitis B reactivation: From biologic  
355 therapies for psoriasis to immunosuppressive therapies for COVID-19. *Experimental and  
356 Therapeutic Medicine*. 2022 Jun 1;23(6):1-9.
- 357 10. Ronderos D, Omar AM, Abbas H, Makker J, Baiomi A, Sun H, Mantri N, Choi Y,  
358 Fortuzi K, Shin D, Patel H. Chronic hepatitis-C infection in COVID-19 patients is  
359 associated with in-hospital mortality. *World Journal of Clinical Cases*. 2021 Oct  
360 10;9(29):8749.
- 361 11. CGHE (2022). National Hepatitis Elimination Profile for Pakistan: Key Takeaways,  
362 National Hepatitis Elimination Profile for Pakistan: Key Takeaways | Coalition for  
363 Global Hepatitis Elimination. The Coalition for Global Hepatitis Elimination (CGHE).  
364 Available at: [https://www.globalhep.org/news/national-hepatitis-elimination-profile-](https://www.globalhep.org/news/national-hepatitis-elimination-profile-pakistan-key-takeaways)  
365 [pakistan-key-takeaways](https://www.globalhep.org/news/national-hepatitis-elimination-profile-pakistan-key-takeaways) (Accessed: October 28, 2022).
- 366 12. Kazmi SA, Rauf A, Shafique F, Asim N, Hassan MU. Kashmiri refugees at the verge of  
367 hepatitis B and C epidemic in the State of Azad Jammu and Kashmir, Pakistan. *Revista  
368 de Saúde Pública*. 2022 May 6;56.
- 369 13. WHO (2022) Vaccines and immunization, World Health Organization. World Health  
370 Organization. Available at: [https://www.who.int/health-topics/vaccines-and-](https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1)  
371 [immunization#tab=tab\\_1](https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1) (Accessed: October 29, 2022).
- 372 14. Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a  
373 new society. *Proceedings of the National Academy of Sciences*. 2014 Aug  
374 26;111(34):12288-93.

- 375 15. Bärnighausen T, Bloom DE, Cafiero-Fonseca ET, O'Brien JC. Valuing vaccination.  
376 Proceedings of the National Academy of Sciences. 2014 Aug 26;111(34):12313-9.
- 377 16. Public Health England, Cambridge University MRC Biostatistics Unit. Direct and  
378 indirect impact of the vaccination programme on COVID-19 infections and mortality.
- 379 17. Galvani A, Moghadas SM, Schneider EC. Deaths and hospitalizations averted by rapid  
380 US vaccination rollout. The Commonwealth Fund. Issue Briefs. 2021 Jul 7.
- 381 18. Government of Pakistan 2022. Covid-19 health advisory platform by Ministry of  
382 National Health Services Regulations and Coordination (2022) COVID. Available at:  
383 <https://covid.gov.pk/stats/pakistan> (Accessed: October 28, 2022).
- 384 19. Hashim, A. (2021). Vaccine hesitancy in Pakistan heightens risk of COVID resurgence.  
385 Al Jazeera.
- 386 20. Weibel, C. (2021) Pakistan steps up COVID-19 vaccine roll-out, UNICEF Pakistan.  
387 Available at: [https://www.unicef.org/pakistan/stories/pakistan-steps-covid-19-vaccine-](https://www.unicef.org/pakistan/stories/pakistan-steps-covid-19-vaccine-roll-out)  
388 [roll-out](https://www.unicef.org/pakistan/stories/pakistan-steps-covid-19-vaccine-roll-out) (Accessed: October 27, 2022).
- 389 21. Barello S, Nania T, Dellafiore F, Graffigna G, Caruso R. 'Vaccine hesitancy' among  
390 university students in Italy during the COVID-19 pandemic. European journal of  
391 epidemiology. 2020 Aug;35(8):781-3.
- 392 22. Abdulsattar, B. (2021) Ipsos survey on vaccine hesitancy in Pakistan - 9th March 2021.  
393 Ipsos. Available at: [https://www.ipsos.com/en-pk/ipsos-survey-vaccine-hesitancy-](https://www.ipsos.com/en-pk/ipsos-survey-vaccine-hesitancy-pakistan-9th-march-2021)  
394 [pakistan-9th-march-2021](https://www.ipsos.com/en-pk/ipsos-survey-vaccine-hesitancy-pakistan-9th-march-2021) (Accessed: October 27, 2022).
- 395 23. Khan A, Afzal S, Yaqoob A, Fatima R, Haq MU, Junaid K, Nadir A. Epidemiology of  
396 viral hepatitis B and C in Punjab, Pakistan: a multicenter cross-sectional study, 2017-18.  
397 F1000Research. 2019 Dec 6;8(2065):2065.
- 398 24. Mustafa ZU, Kow CS, Hasan SS. Effect of COVID-19 on viral hepatitis services in  
399 Pakistan. The Lancet Gastroenterology & Hepatology. 2021 Mar 1;6(3):163-4.
- 400 25. Janz NK, Becker MH. The health belief model: A decade later. Health education  
401 quarterly. 1984 Mar;11(1):1-47.
- 402 26. Shafique F, Nayab H, Asim N, Akbar N, Shafi N, Manzoor S, Eeden FV, Ali S. Attitude  
403 and perception towards vaccination against poliomyelitis in Peshawar, Pakistan. Revista  
404 de Saúde Pública. 2021 Dec 8;55:104.

- 405 27. Tahir MJ, Saqlain M, Tariq W, Waheed S, Tan SH, Nasir SI, Ullah I, Ahmed A.  
406 Population preferences and attitudes towards COVID-19 vaccination: a cross-sectional  
407 study from Pakistan. *BMC public health*. 2021 Dec;21(1):1-2.  
408 <https://doi.org/10.1186/s12889-021-11814-5>
- 409 28. Palla P, Vergadis C, Sakellariou S, Androutsakos T. Autoimmune hepatitis after  
410 COVID-19 vaccination: A rare adverse effect?. *Hepatology (Baltimore, Md.)*. 2022  
411 Feb;75(2):489.
- 412 29. Camacho-Domínguez L, Rodríguez Y, Polo F, Gutierrez JC, Zapata E, Rojas M, Anaya  
413 JM. COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and  
414 review of the literature. *Journal of translational autoimmunity*. 2022 Jan 4:100140.
- 415 30. Bril F, Al Diffalha S, Dean M, Fettig DM. Autoimmune hepatitis developing after  
416 coronavirus disease 2019 (COVID-19) vaccine: causality or casualty?. *Journal of*  
417 *Hepatology*. 2021 Jul 1;75(1):222-4.
- 418 31. Garrido, I., Lopes, S., Simões, M.S., Liberal, R., Lopes, J., Carneiro, F. and Macedo, G.,  
419 2021. Autoimmune hepatitis after COVID-19 vaccine—more than a coincidence. *Journal*  
420 *of Autoimmunity*, 125, p.102741.
- 421 32. Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera de la Tijera F, Aloman C, Rıza  
422 Çalışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM. Outcome of COVID-19 in  
423 patients with autoimmune hepatitis: an international multicenter study. *Hepatology*. 2021  
424 Jun;73(6):2099-109.
- 425 33. Jain VK, Iyengar KP, Ish P. Elucidating causes of COVID-19 infection and related deaths  
426 after vaccination. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2021  
427 Sep 1;15(5):102212.
- 428 34. Fernandez-Davila N, Taylor MG, Anvari S. Hypersensitivity Reactions to COVID-19  
429 Vaccines—Identify High-Risk Children and Vaccinate the Rest. *JAMA pediatrics*. 2022  
430 May 1.
- 431 35. Kissler S, Tedijanto C, Lipsitch M, Grad YH. Social distancing strategies for curbing the  
432 COVID-19 epidemic. *MedRxiv*. 2020 Jan 1.
- 433 36. Moosa IA. The effectiveness of social distancing in containing Covid-19. *Applied*  
434 *Economics*. 2020 Dec 13;52(58):6292-305.



- 435 37. Hsieh CC, Lin CH, Wang WY, Pauleen DJ, Chen JV. The outcome and implications of  
436 public precautionary measures in Taiwan–Declining respiratory disease cases in the  
437 COVID-19 pandemic. *International journal of environmental research and public health*.  
438 2020 Jul;17(13):4877.
- 439 38. Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj SB, Ghammam R, Ghannem H.  
440 Effective public health measures to mitigate the spread of COVID-19: a systematic  
441 review. *BMC public health*. 2021 Dec;21(1):1-4.

442 **Tables:**

443 **Table 2-show demographic data frequencies of the participants. (n = 839).**

No.	Demographic variables	Number (n)	Percentage (%)
<b>1</b>	<b>Age (years)</b>		
	18-30	479	57.1
	31-40	164	19.5
	41-55	151	18.0
	56->65	45	5.4
<b>2</b>	<b>Gender</b>		
	Male	536	63.9
	Female	303	36.1
<b>3</b>	<b>Qualification</b>		
	Nil	79	9.4
	Primary	50	6.0
	Secondary	49	5.8
	Intermediate	86	10.3
	Graduate	329	39.2
	Post-graduate	246	29.3
<b>4</b>	<b>Employment status</b>		
	Unemployed or Housewives	211	25.1
	Students	83	9.9
	Paid-employed	289	34.4
	Self-employed	256	30.5
<b>5</b>	<b>Monthly Income (PKR)</b>		
	< 30,000	513	61.1
	> 30,000	326	38.9
<b>6</b>	<b>Ethnicity</b>		
	Pathan	405	48.3
	Kashmiri	353	42.1
	Punjabi	64	7.6
	others	17	2.0
<b>7</b>	<b>Location</b>		
	Peshawar KPK	432	51.5
	Muzaffarabad AJK	407	48.5

<b>8</b>	<b>Hepatitis B positive</b>
----------	-----------------------------

**a. Question Statements**

	No	436	52.0
	Yes	403	48.0
<b>9</b>	<b>Hepatitis C positive</b>		
	No	403	48.0
	Yes	436	52.0
<b>10</b>	<b>Covid-19 vaccination</b>		
	No	298	35.5
	Yes	541	64.5

444

445 **Table 2- Commercially available Vaccines approved by the Government of Pakistan.**

<b>Approved Vaccines</b>	<b>Type of vaccine</b>
Moderna mRNA 1273	RNA
Pfizer/BioNTech BNT 162b2	RNA
Consino Ad5-NCov	Non-Replicating viral Vector
Gamaleya Spuntik V	Non-Replicating viral Vector
Oxford /Astrazeneca AZD1222	Non-Replicating viral Vector

446

447

**Table 3a. Assessment of patients choosing COVID-19 vaccine for protection. Table 2B. Question statements to assess Hepatitis patient for refusing COVID-19 vaccine.**

<b>Part A: Why should a hepatitis B or C positive should take Covid-19 Vaccine?</b>	<b>Responses (n=839)</b>	
	No. of participants responded "Yes"	Percentage
I think there is no harm in taking Covid-19 vaccine.	477	72.4%
I believe Covid-19 vaccination will be useful in protecting the Covid-19 infection	507	76.9%
Covid-19 vaccine is available free of cost.	524	79.5%
My healthcare professionals and doctors has recommended me	469	71.2%
I believe that the benefits of COVID-19 vaccine are more than the risk involved	415	63.0%
I believe that taking Covid-19 vaccine is social responsibility	435	66.0%
There is sufficient data regarding the vaccine safety and efficacy released by the government.	374	56.8%
Many other hepatitis B and C are taking COVID-19 Vaccine	504	76.5%

**b. Question Statements**

<b>Part B: Reason to refuse COVID-19 vaccine</b>	<b>Responses (n=294)</b>	
	No. of patients responded "Yes"	Percentage
I think that it will damage my liver more.	161	54.7 %
I think that COVID-19 vaccine will affect my hepatitis therapy	181	61.5 %
I think that strict SOPs can make me prevent from infection.	218	74.1 %
I do not have enough information about the vaccine.	186	63.2 %
I am against vaccine in general.	158	53.7 %
Due to previous infection with COVID-19, I don't need vaccine	172	58.5 %
People still got covid infection after getting vaccine.	169	57.5 %
After getting first dose I developed some allergic reactions	36	12.2%

448

449 **Table 4a. Correlation between different variables of Hepatitis B and C patients with the Covid-19**  
 450 **vaccine approval or rejection. b. Spearman correlation between different variables and COVID-19**  
 451 **vaccine.**

452


**a.**

Variables	Gender	education	location	income	Occupation	Ethnicity	Hepatitis B	Hepatitis C	Covid vaccine	COV 2nd dose	COV booster
Age	↑ 0.124	↘ -0.126	↘ 0.03	↘ 0.016	↘ -0.03	↘ -0.004	↘ -0.126	↑ 0.126	↘ 0.033	↘ -0.015	↑ 0.07
Gender		↑ 0.064	↘ -0.055	↘ -0.095	↑ 0.057	↘ 0.025	↘ -0.08	↑ 0.087	↘ -0.018	↑ 0.093	↘ -0.046
education			↘ -0.137	↘ -0.041	↘ 0.023	↑ 0.05	↑ 0.081	↘ -0.081	↑ 0.09	↑ 0.182	↘ -0.005
location				↑ 0.058	↘ 0.009	↘ -0.034	↘ -0.06	↑ 0.06	↘ -0.022	↑ 0.048	↑ 0.094
income					↘ 0.044	↑ 0.095	↑ 0.075	↘ -0.075	↘ -0.119	↘ -0.106	↑ 0.083
Occupation						↑ 0.082	↘ 0.007	↘ -0.007	↑ 0.104	↑ 0.07	↑ 0.103
Ethnicity							↘ 0.03	↘ -0.03	↘ -0.064	↑ 0.083	↘ 0.044
Hepatitis B								↓ -1	↘ 0.041	↑ 0.096	↘ 0.006
Hepatitis C									↘ -0.041	↘ -0.096	↘ -0.006
Covid vaccine										↑ 0.394	↘ 0.028
COV 2nd dose											↑ 0.209

**b.**

Variables	Spearman Correlation r	P Value (0.05)
Age	0.033	0.340
Gender	-0.018	0.612
Education	0.064	0.064
Location	-0.022	0.522
Income	-.119	<b>0.001**</b>
Occupation	.107	<b>0.002**</b>
Ethnicity	-0.035	0.309
Hepatitis B	0.041	0.240
Hepatitis C	-0.041	0.240

454 **Figures:**



455

456 **Figure 2a. No. of patients receiving Covid vaccines from approved pharmaceuticals. b. No. of**  
 457 **Patients refused to get immunized.**

458